Volume 92, Issue 1, Pages (July 2017)

Slides:



Advertisements
Similar presentations
Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes Featured Article: Andrzej S. Krolewski, M.D., Ph.D., James H. Warram,
Advertisements

Volume 82, Issue 12, Pages (December 2012)
From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.
Improved prognosis of diabetic nephropathy in type 1 diabetes
Chronic Kidney Disease in Diabetes
Volume 80, Issue 1, Pages (July 2011)
Volume 80, Issue 1, Pages (July 2011)
Volume 85, Issue 5, Pages (May 2014)
Volume 58, Issue 1, Pages (July 2000)
Volume 93, Issue 1, Pages (January 2018)
Volume 79, Issue 12, Pages (June 2011)
Volume 92, Issue 2, Pages (August 2017)
Volume 93, Issue 1, Pages (January 2018)
Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan 
Volume 80, Issue 9, (November 2011)
Chronic Kidney Disease in Diabetes
Volume 80, Issue 1, Pages (July 2011)
Mortality caused by sepsis in patients with end-stage renal disease compared with the general population  Mark J. Sarnak, Bertrand L. Jaber  Kidney International 
Volume 80, Issue 2, Pages (July 2011)
Volume 66, Issue 1, Pages (July 2004)
Volume 82, Issue 12, Pages (December 2012)
Volume 54, Issue 2, Pages (August 1998)
Volume 86, Issue 4, Pages (October 2014)
Your Kidneys May Outlive You
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration 
The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age  B.O. Eriksen, O.C. Ingebretsen  Kidney International 
Volume 92, Issue 1, Pages (July 2017)
Volume 79, Issue 12, Pages (June 2011)
Volume 66, Issue 3, Pages (September 2004)
Volume 93, Issue 1, Pages (January 2018)
End-stage renal disease in living kidney donors
Volume 69, Issue 2, Pages (January 2006)
Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian, Yan Yan, Ziyad Al-Aly 
Survival advantage in Asian American end-stage renal disease patients1
Volume 91, Issue 1, Pages (January 2017)
Volume 77, Issue 7, Pages (April 2010)
Renal risk scores: Progress and prospects
Bariatric surgery is associated with improvement in kidney outcomes
Long-term outcomes in nondiabetic chronic kidney disease
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Volume 85, Issue 6, Pages (June 2014)
U-shaped effect of eGFR and mortality
Volume 70, Issue 12, Pages (December 2006)
Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?  Pantelis A. Sarafidis, Luis.
Volume 90, Issue 5, Pages (November 2016)
Volume 58, Issue 1, Pages (July 2000)
Proteinuria and hypertensive nephrosclerosis in African Americans
Methods for guideline development
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.
Improved prognosis of diabetic nephropathy in type 1 diabetes
Volume 85, Issue 5, Pages (May 2014)
Volume 73, Issue 8, Pages (April 2008)
Volume 67, Issue 5, Pages (May 2005)
Volume 81, Issue 7, Pages (April 2012)
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Volume 76, Issue 6, Pages (September 2009)
Volume 83, Issue 3, Pages (March 2013)
Volume 80, Issue 10, Pages (November 2011)
Volume 90, Issue 3, (September 2016)
Volume 60, Issue 3, Pages (September 2001)
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Volume 75, Issue 1, Pages (January 2009)
Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley 
Assessing the impact of different imputation methods on serial measures of renal function: The Strong Heart Study  N.-M. Shara, J.-G. Umans, W. Wang,
Adiponectin: good, bad, or just plain ugly?
A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan  Yi-Chun.
Friends, social networks, and progressive chronic kidney disease
Volume 73, Issue 11, Pages (June 2008)
Implementing the European Renal Best Practice Guidelines suggests that prediction equations work well to differentiate risk of end-stage renal disease vs.
Volume 60, Issue 1, Pages (July 2001)
Presentation transcript:

Volume 92, Issue 1, Pages 258-266 (July 2017) Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end- stage renal disease  Masayuki Yamanouchi, Jan Skupien, Monika A. Niewczas, Adam M. Smiles, Alessandro Doria, Robert C. Stanton, Andrzej T. Galecki, Kevin L. Duffin, Nick Pullen, Matthew D. Breyer, Joseph V. Bonventre, James H. Warram, Andrzej S. Krolewski  Kidney International  Volume 92, Issue 1, Pages 258-266 (July 2017) DOI: 10.1016/j.kint.2017.02.010 Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 1 Prognostic cut-points derived from the multimarker analysis of the combined type 1 diabetes (T1D) and type 2 diabetes (T2D) cohorts. Plots of the cumulative risk of a study outcome within 3 years in T1D patients (solid line) and T2D patients (interrupted line). Sex, age, systolic blood pressure, hemoglobin A1c, estimated glomerular filtration rate, and tumor necrosis factor receptor (TNFR) 2 were included in the classification and regression tree analysis, but none surpassed the outcome separation achieved by TNFR1 and albumin-to-creatinine ratio (ACR). Letters (a), (b), and (c) in each plot refer to the corresponding areas in Figure 2. Kidney International 2017 92, 258-266DOI: (10.1016/j.kint.2017.02.010) Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 2 Distribution of patient outcomes in the combined study group (type 1 diabetes [T1D] and type 2 diabetes [T2D]) according to baseline values of tumor necrosis factor receptor (TNFR) 1 and albumin-to-creatinine ratio (ACR). Outcomes during the 3-year follow-up are color coded according to type: end-stage renal disease (ESRD) (red), 40% baseline estimated glomerular filtration rate (eGFR) loss (blue), deaths unrelated to ESRD (black ×), or no event (none) (open circle). The cut-points for TNFR1 (2.9 ng/ml and 4.3 ng/ml) and ACR (1900 mg/g) shown in Figure 1 are represented by interrupted horizontal and vertical lines, respectively. The dots within the areas labeled (a), (b), and (c) represent the patients in Figure 1 plots with the corresponding labels. The gray area indicates high risk, whereas the white area indicates a low risk of the outcome. Note that the distributions of blue and red dots closely overlap. Kidney International 2017 92, 258-266DOI: (10.1016/j.kint.2017.02.010) Copyright © 2017 International Society of Nephrology Terms and Conditions

Figure 3 Cumulative incidence of end-stage renal disease (ESRD) (interrupted line) and ESRD and deaths (solid line) in patients who are not eligible for a clinical trial according to the multimarker prognostic criterion. (a) Type 1 diabetes (T1D) patients (n = 160) and (b) type 2 diabetes (T2D) patients (n = 142). While the incidence of ESRD and mortality was low within the first 3 years, by the 10th year of follow-up, it reached 45% and 63% in T1D and T2D patients, respectively. Overall, during the 10 years of follow-up, 48 ESRD cases occurred in the T1D cohort and 38 in the T2D cohort that were not eligible by the multimarker criterion. Kidney International 2017 92, 258-266DOI: (10.1016/j.kint.2017.02.010) Copyright © 2017 International Society of Nephrology Terms and Conditions